HUTCHMED (China) Limited (HK:0013) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HUTCHMED (China) Limited has announced that its New Drug Application for the combination of ORPATHYS® and TAGRISSO® in treating lung cancer patients with MET amplification has been accepted for priority review in China. This marks a significant step for the company, as the combination aims to offer a chemotherapy-free, all-oral treatment option for patients with resistant non-small cell lung cancer. The acceptance also triggers a milestone payment from AstraZeneca, highlighting the potential impact of this innovative therapy on the lung cancer treatment landscape.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Amazon’s (NASDAQ:AMZN) Return-to-Office Mandate Comes With Unexpected Issue
- Ford (NYSE:F) Bonds Prove Tempting, Fuel Pumps Less So
- Intel (NASDAQ:INTC) Augments LG Laptops, Faces Challenges
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
